Barr buys incontinence product rights
Executive Summary
Barr acquires worldwide rights to Phase II oxybutynin transvaginal ring under an agreement with Schering AG. Barr has been developing the incontinence agent for Schering AG since its acquisition of Enhance Pharmaceuticals in 2002 (1"The Pink Sheet" April 1, 2002, p. 30)...